Evaluation of a nanosuspension formulation prepared through microfluidic reactors for pulmonary delivery of budesonide using nebulizers
Authors
Abstract:
This study aimed to determine the aerosolization behavior of a nanodispersion of budesonide, prepared using microfluidic reactors. The size and morphology of budesonide nanoparticles were characterized by photon correlation spectroscopy (PCS) and transmission electron microscopy (TEM). Processing/formulation parameters for formation of the nanoparticles were studied to determine their effects on the particle size. Results showed a narrow distribution for budesonide nanodispersion with spherical and smooth surfaced particles. To investigate the in-vitro aerosolization performance of the nanodispersion, the preparation was compared with a commercially available budesonide microsuspension using the Comité Européen Normalization (CEN) methodology. Aerosolization results showed that the fine particle fraction (FPF) generated from the budesonide nanodispersion was significantly higher than that of the marketed budesonide (ie. mean (SD) 56.88 (3.37)% vs. 38.04 (7.82)%, respectively). Additionally, mass median aerodynamic diameter (MMAD) of nano-budesonide dispersion was significantly smaller than the microsuspension (ie. mean (SD) 3.91 (0.49) vs. 6.22 (1.09) µm, respectively), with nebulization time of nano-budesonide dispersion significantly shorter than the marketed budesonide microsuspension (ie. 12.3 (0.37) vs. 14.85 (0.36) min, respectively). The produced nanodispersion was found to be stable over a period of 10 days if stored at 4 °C.
similar resources
evaluation of a nanosuspension formulation prepared through microfluidic reactors for pulmonary delivery of budesonide using nebulizers
this study aimed to determine the aerosolization behavior of a nanodispersion of budesonide, prepared using microfluidic reactors. the size and morphology of budesonide nanoparticles were characterized by photon correlation spectroscopy (pcs) and transmission electron microscopy (tem). processing/formulation parameters for formation of the nanoparticles were studied to determine their effects o...
full textEvaluation of a Nanodispersion Formulation Prepared through Microfluidic Reactors for Pulmonary Delivery of Budesonide Using Nebulizers
This study aimed to determine the aerosolization behavior of a nanodispersion of budesonide, prepared using microfluidic reactors. The size and morphology of budesonide nanoparticles were characterized by photon correlation spectroscopy (PCS) and transmission electron microscopy (TEM). Processing/formulation parameters for formation of the nanoparticles were studied to determine their effects o...
full textNanosizing and In-vitro Characterization of Budesonide Dispersions Prepared by Microfluidic Reactors
Address: 1Institute of Pharmaceutical Innovation, University of Bradford, Richmond Rd., Bradford, BD7 1DP, U.K., 2Department of Pharmaceutics, Pharmacy Faculty, Assiut University, Assiut 71515, Egypt, 3Biotechnology Research Center and Pharmacy, Faculty and Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 51664, Iran, 4Department of Chemistry, University of North Texa...
full textEvaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery
Asthma and chronic obstructive pulmonary disease (COPD) are pulmonary diseases that are characterized by inflammatory cell infiltration, cytokine production, and airway hyper-reactivity. Most of the effector cells responsible for these pathologies reside in the lungs. One of the most direct ways to deliver drugs to the target cells is via the trachea. In a pre-clinical setting, this can be achi...
full textFormulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken design
Budesonide is a potent non-halogenated corticosteroid with high anti-inflammatory effects. The lungs are an attractive route for non-invasive drug delivery with advantages for both systemic and local applications. The aim of the present study was to develop, characterize and optimize a solid lipid nanoparticle system to deliver budesonide to the lungs. Budesonide-loaded solid lipid nanoparticle...
full textMy Resources
Journal title
volume 13 issue 3
pages 785- 795
publication date 2014-07-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023